key: cord-0900102-enl5gac9 authors: Gendrot, Mathieu; Andreani, Julien; Duflot, Isabelle; Boxberger, Manon; Bideau, Marion Le; Mosnier, Joel; Jardot, Priscilla; Fonta, Isabelle; Rolland, Clara; Bogreau, Hervé; Hutter, Sébastien; La Scola, Bernard; Pradines, Bruno title: Methylene blue inhibits the replication of SARS-Cov-2 in vitro date: 2020-10-16 journal: Int J Antimicrob Agents DOI: 10.1016/j.ijantimicag.2020.106202 sha: 22697c756b9e955d3b1685cba77a28e41b75b989 doc_id: 900102 cord_uid: enl5gac9 In December 2019, a new severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing coronavirus diseases 2019 (COVID-19) emerged in Wuhan, China. Currently, there is no antiviral treatment recommended against SARS-CoV-2. Identifying effective antiviral drugs is urgently needed. Methylene blue already demonstrated in vitro antiviral activity in photodynamic therapy, and antibacterial, antifungal or antiparasitic activity in nonphotodynamic assays. Non-photoactivated methylene blue showed in vitro activity at very low-micromolar range with EC(50) of 0.3 ± 0.03 µM and EC(90) of 0.75 ± 0.21 µM at MOI of 0.25 against SARS-CoV-2. The EC(50) and EC(90) values for methylene blue are lower than those obtained for hydroxychloroquine (1.5 and 3.0 µM) and azithromycin (20.1 and 41.9 µM). The ratios C(max)/EC(50) and C(max)/EC(90) in blood for methylene blue after oral administration were estimated at 10.1 and 4.0, respectively, and 33.3 and 13.3 after intravenous administration. Methylene blue EC(50) and EC(90) are consistent with concentrations observed in human blood. We propose that methylene blue is a promising drug for COVID-19 treatment. In vivo evaluation in animal experimental models is now required to confirm its antiviral effects on SARS-CoV-2. The potential interest of methylene blue to treat COVID-19 needs to be confirmed by prospective comparative clinical studies. In December 2019, a new severe acute respiratory syndrome coronavirus (SARS-CoV-2) causing coronavirus diseases 2019 (COVID-19) emerged in Wuhan, China [1] . Despite containment measures, SARS-CoV-2 spread in Asia, Southern Europe, then in America and currently in Africa. Currently, there is no antiviral treatment recommended against SARS-CoV-2. Different drugs or combination have been evaluated worldwide. Identifying effective low cost antiviral drugs with limited side effects affordable immediately is urgently needed, especially for emerging countries. Plasma products can transmit a wide range of pathogens in transfusion. Methylene blue, a synthesized thiazine dye, was known to be effective in photodynamic therapy against microbes and more especially virus. Methylene blue is able to intercalate into viral nucleic acid when illuminated with visible light and prevents transmission of pathogens. The illumination of methylene blue inactivated Zika, yellow fever, dengue, chikungunya, Ebola viruses and Middle East respiratory syndrome coronavirus in plasma [2] [3] [4] [5] . Methylene blue can also demonstrate antimicrobial activities without photoactivation. Methylene blue inhibited in vitro colistin-resistant strains of Acinetobacter baumannii, Mycobacterium ulcerans, Mycobacterium spp. and Candida albicans [6] [7] [8] . Methylene blue was also effective in vivo against Buruli ulcer in experimental Mycobacterium ulcerans infection in mice [7] . Additionally, methylene blue inactivated hepatis C virus in transplant organ perfused with methylene blue [9] . The most studied effects are those on malaria. In 1891, methylene blue was first used to treat effectively two patients with uncomplicated malaria [10] . In the 2010s, methylene blue showed effective in vitro activity in the nanomolar range against Plasmodium falciparum strains and isolates [11] [12] [13] [14] . Methylene blue showed a protective effect against cerebral malaria in a murine model infected with P. berghei [15] [16] [17] . Methylene blue showed several benefits when used as partner in triple combination with artemisinin-based combination therapy in uncomplicated falciparum malaria in children [18] . Taken together, these reports suggest that methylene blue may have antiviral effects against SARS-CoV-2. Therefore the activity of methylene blue was assessed in vitro against a clinically isolated SARS-CoV-2 strain and compared with the activity of hydroxychloroquine and azithromycin, which have been already evaluated in vitro and in vivo in human [19] [20] [21] [22] . In vitro cell viability evaluation on the VERO E6 cell line was performed according to the method described by Mosmann with slight modifications [24] . Briefly, 10 5 cells in 200 µl of complete medium were added to each well of 96-well plates and incubated at 37 °C in a humidified 5% CO 2 . After 24 h incubation, 25 µl of complete medium and 25 µl of each concentration of methylene blue, hydroxychloroquine or azithromycin were added and the plates were incubated 48h at 37 °C. After removal of the surpernatant, 100 µL of MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide, Sigma Aldrich, France) solution (0.5 mg/ml in MEM without FBS) were then added to each well. Cells were incubated for 2 h at 37 °C. After incubation, the MTT solution was removed and 100 µl of dimethyl sulfoxide (DMSO) was added to dissolve the formazan crystals. Then, plates were shaken at 700 rpm for 10 min at 37 °C. The absorbance was measured at 570 nm using a TECAN Infinite F200 Microplate Reader. DMSO was used as blank. The 50% cytotoxicity concentration (CC 50 ) was calculated with the inhibitory sigmoid E max model, which estimated the CC 50 through nonlinear regression by using a standard function of the R software (ICEstimator version 1.2, http://www.antimalarial-icestimator.net). CC 50 value resulted in the mean of 6 different experimentations. Briefly, 96-well plates were prepared with 5.10 5 cells/mL of Vero E6 (200µL per well), as previously described [20] . Methylene blue, hydroxychloroquine or azithromycin concentrations were added 4 h before infection. Vero E Cells were infected with IHUMI-3 strain at an MOI of 0.25. After 48h post-infection, the replication was estimated by RT-PCR using the Superscrit III platinum one step with Rox kit (Invitrogene) after extraction with the BIoExtract SuperBall kit (Biosellal, Dardilly, France). The primers used were previously described [25] . EC 50 (median effective concentration) and EC 90 (90% effective concentration) were calculated with the inhibitory sigmoid E max model, which estimated the EC 50 and EC 90 through nonlinear regression by using a standard function of the R software (ICEstimator version 1.2). EC 50 and EC 90 values resulted in the mean of 6 different experimentations. Selectivity index (SI) as ratio of CC 50 /EC 50 was estimated for each drug. The expected maximum blood concentration (C max ) was estimated from literature for each drug at doses commonly administered in oral malaria treatment, and for methylene blue at intravenous doses used for FDA and MEA approved methemoglobinemia treatment. The ratios C max /EC 50 and C max /EC 90 were estimated to find out if the effective concentration in plasma to cure SARS-CoV-2 is achievable in human. If data on drug accumulation into lung was available, the ratios C lung /EC 50 and C lung /EC 90 were calculated. CC 50 , EC 50 , EC 90 and SI for each drug are presented in Table 1 . Methylene blue and hydroxychloroquine showed EC 50 and EC 90 at low micromolar range ( Table 1 ). The EC 50 and EC 90 values for methylene blue are lower than those obtained for hydroxychloroquine and azithromycin. The ratios C max /EC 50 and C max /EC 90 in blood for methylene blue were estimated at 10.1 and 4.0, respectively after oral administration and at 33.3 and 13.3 after intravenous administration ( Figure 1 ). Methylene blue showed in vitro activity at very low-micromolar range with EC 50 of 0.3 ± 0.03 µM and EC 90 of 0.75 ± 0.21 µM at MOI of 0.25 (SI > 333) ( Table 1 ). The EC 50 and EC 90 values for methylene blue are lower than those obtained for hydroxychloroquine and azithromycin. Azithromycin demonstrated low in vitro efficacy against SARS-CoV-2 used alone but potentiated the effects of hydroxychloroquine in combination [20] . An oral uptake of 325 mg of methylene blue led to a C max (maximum blood concentration) value of 0.97 µg/ml (around 3 µM) and t 1/2 (elimination half-life) of 14.9 h [26] . Methylene blue dose of 2 mg/kg intravenous showed a C max of 2.917 µg/ml (around 10 µM) [27] . The ratios C max /EC 50 and C max /EC 90 for methylene blue were estimated at 10.1 and 4.0 for oral route and 33.3 and 13.3 for IV, respectively. Methylene blue EC 50 and EC 90 are consistent with concentrations observed in human blood. Around 3 to 5% of methylene blue per g of lung was found after intravenous methylene blue injection but methylene blue concentration decreased rapidly under 0.1% after 10 h [28] . In comparison, an oral uptake of 400 mg of hydroxychloroquine led to a C max of 1.22 µM [29] . Hydroxychloroquine accumulated 30 times more in lungs than in blood [30] . The azithromycin C max ranged from 0.18 to 0.4 µg/ml of blood (around 0.22 to 0.51 µM) after the last dose of oral administration of 500 mg once daily for 3 days or after a single dose of 500 mg [31] [32] [33] . These doses led to C max in lung ranging from 8 to 9 µg/g (around 10 to 12 µM) [31, 32] . The C max expected in lung was below the EC 50 and EC 90 . However, due to potentiation of the antiviral effects when azithromycin is combined with hydroxychloroquine, azithromycin can be used in vitro at lower concentrations (5 and 10 µM) [20] . These concentrations are compatible with expected concentrations in lungs. Methylene blue showed a low cytotoxicity in vitro against Vero E6 cells with CC 50 > 100 µM. The selectivity index (SI) as ratio of CC 50 /EC 50 was estimated above 333. The present CC 50 of hydroxychloroquine with SI around 13 against Vero E6 cells was higher than previous reported CC 50 , ranging from > 50 µM to 250 µM against Vero E6 cells [19, 34] or above 500µM in Felis catus whole fetus-4 cells [35] . Azithromycin showed also a low cytotoxicity against Vero E6 cells with CC 50 > 100 µM and SI > 5. CC 50 for azithromycin was consistent with previous data (> 130) [34] . Methylene blue showed a low cytotoxicity but predominatingly the higher SI. Although methylene blue is on the list of drugs potentially dangerous for patients with glucose-6-phosphate dehydrogenase (G6PD), no association between methylene blue and severe hemolysis has been detected after oral administration [36] . Additionally, IV route methylene blue has been granted a Market authorization in Europe in 2011 and in the US in 2016, for the treatment of acquired methemoglobinemia, based upon a confirmed positive benefit/risk ratio in this pathology. Methylene blue showed high in vitro antiviral effective activity against SARS-CoV-2 with A new coronavirus associated with human respiratory disease in China Dengue and chikungunya viruses in plasma are effectively inactivated after treatment with methylene blue and visible light Inactivation of yellow fever virus in plasma after treatment with methylene blue and visible light and in platelet concentrates following treatment with ultraviolet C light Inactivation of Zika virus in plasma and derivatives by four different methods Inactivation of Ebola virus and Middle East respiratory syndrome coronavirus in platelet concentrates and plasma by ultraviolet C light and methylene blue plus visible light In vitro activity of methylene blue and eosin methylene blue agar on colistin-resistant A. baumannii: an experimental study Effectiveness of purified methylene blue in an experimental model of Mycobacterium ulcerans infection Nonphotodynamic roles of methylene blue: Display of distinct antimycobacterial and anticandidal mode of actions Methylene blue treatment of grafts during cold ischemia time reduces the risk of hepatitis C virus transmission Ueber die Wirkung des Methylenblau bei Malaria Proveblue (methylene blue) on Plasmodium falciparum strains resistant to standard antimalarial drugs Plasmodium falciparum susceptibility to standard and potential anti-malarial drugs in Dakar, Senegal, during the 2013-2014 malaria season Ex vivo activity of Proveblue, a methylene blue, against filed isolates of Plasmodium falciparum in Dakar, Senegal from 2013 to 2015 Baseline and multinormal distribution of ex vivo susceptibilities of Plasmodium falciparum to methylene blue in Africa Dose responses of Proveblue methylene blue in an experimental murine cerebral malaria model Efficacy of Proveblue (methylene blue) in an experimental cerebral malaria murine model Impact of methylene blue and atorvastatin combination therapy on the apparition of cerebral malaria in a murine model Safety and efficacy of artesunate-amodiaquine combined with either methylene blue or primaquine in children with falciparum malaria in Burkina Faso: A randomized controlled trial Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro In vitro testing of hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect COVID-19 patients with at least a six-day follow up: an observational study Early treatment of 1061 COVID-19 patients with hydroxychloroquine and azithromycin Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infection diseases referral hospital Pharmacokinetics and ex vivo antimalarial activity of artesunate-amodiaquine plus methylene blue in healthy volunteers Center for drug evaluation and research. Clinical pharmacology and biopharmaceutics review(s): Application number 204630Orig1s000 Targeting disseminated melanoma with radiolabelled methylene blue Therapy and pharmacological properties of hydroxychloroquine and chloroquine in the treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases Simultaneous quantification of hydroxychloroquine and its metabolites in mouse blood and tissues using LC-ESI-MS/MS: An application for pharmacokinetic studies Comparative distribution of azithromycin in lung tissue of patient given oral daily doses of 500 and 1000 mg Pharmacokinetics of azithromycin in serum, bronchial washings, alveolar macrophages and lung tissue following a single oral dose of extended or immediate release formulations of azithromycin In vitro activity and pharmacodynamic/pharmacokinetic parameters of clarithromycin and azithromycin: why they matter in the treatment of respiratory tract infections Evaluation of Ebola virus inhibitors for drug repurposing Antiviral effects oh hydroxychloroquine and type I interferon on in vitro fatal feline coronavirus infection Efficacy and safety of methylene blue in the treatment of malaria: a systemic review Remdesivir, lopinavir, emetine, and homoharringtonine inhibits SARS-CoV-2 replication in vitro The authors thank Provepharm for providing the methylene blue (Proveblue®)